Molecular Formula | C17H14ClIO3 |
Molar Mass | 428.65 |
Density | 1.639 |
Melting Point | 109-113oC |
Boling Point | 526℃ |
Flash Point | 272℃ |
Solubility | Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly) |
Appearance | Solid |
Color | Off-White to Pale Beige |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.333 ml | 11.665 ml | 23.329 ml |
5 mM | 0.467 ml | 2.333 ml | 4.666 ml |
10 mM | 0.233 ml | 1.166 ml | 2.333 ml |
5 mM | 0.047 ml | 0.233 ml | 0.467 ml |
Overview | (2-chloro-5-iodophenyl)[4-[[(3S)] tetrahydro-3-furyl] oxy] phenyl] methanone belongs to ketone organic compounds, is a pharmaceutical intermediate, and can be used for preparing C- aryl glucoside SGLT2 inhibitors having the following general formula. This product is an intermediate of emparizine, a potent and selective SGLT-2 inhibitor that improves glycemic control syndrome in diabetic rats. |
Application | (2-chloro-5-iodophenyl)[4-[[(3S)]-Tetrahydro-3-furyl] oxy] phenyl] methanone belongs to ketone organic compounds and can be used for the preparation of C- aryl glucoside SGLT2 inhibitors having the following general formula. SGLT2 is the major Na/glucose cotransporter in epithelial cells of the proximal tubule S1 segment and is responsible for 90% of glucose reabsorption in the kidney. SGLT2 inhibitors can inhibit renal glucose reabsorption, bring diabetic patients to normal plasma glucose levels through urinary glucose excretion, thereby increasing insulin sensitivity and delaying the development of diabetic complications. |